|
1
|
Chen T, Jansen L, Gondos A, Emrich K,
Holleczek B, Luttmann S, Waldmann A and Brenner H: Gekid cancer
survival working group. Survival of cervical cancer patients in
Germany in the early 21st century: A period analysis by age,
histology, and stage. Acta Oncol. 51:915–921. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
McLemore MR, Miaskowski C, Aouizerat BE,
Chen LM and Dodd MJ: Epidemiological and genetic factors associated
with ovarian cancer. Cancer Nurs. 32:281–288. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yoneda A, Lendorf ME, Couchman JR and
Multhaupt HA: Breast and ovarian cancers: A survey and possible
roles for the cell surface heparan sulfate proteoglycans. J
Histochem Cytochem. 60:9–21. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Moghaddam SM, Amini A, Morris DL and
Pourgholami MH: Significance of vascular endothelial growth factor
in growth and peritoneal dissemination of ovarian cancer. Cancer
Metastasis Rev. 31:143–162. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Saad AF, Hu W and Sood AK:
Microenvironment and pathogenesis of epitelial ovarian cancer. Horm
Cancer. 1:277–290. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Popa Z, Chiriac VD, Cobec IM, Lungeanu D,
Craina M, Bernad E, Ionita I, Moleriu RD, Iacob D and Petre I: HPV
cervical cancer screening. An analysis over HPV markers between
worldwide statistics and Romanian reality. Rev Chim. 68:2459–2462.
2017.
|
|
7
|
Rosen DG, Yang G, Liu G, Mercado-Uribe I,
Chang B, Xiao XS, Zheng J, Xue FX and Liu J: Ovarian cancer:
Pathology, biology, and disease models. Front Biosci (Landmark Ed).
14:2089–2102. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Kim A, Ueda Y, Naka T and Enomoto T:
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin
Cancer Res. 31(14)2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lalwani N, Prasad SR, Vikram R, Shanbhogue
AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic
features of ovarian cancers: Implications for diagnosis and
treatment. Radiographics. 31:625–646. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cho KR and Shih IM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Barua A, Bitterman P, Abramowicz JS, Dirks
AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J and
Luborsky JL: Histopathology of ovarian tumors in laying hens: A
preclinical model of human ovarian cancer. Int J Gynecol Cancer.
19:531–539. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shih IM and Davidson B: Pathogenesis of
ovarian cancer: Clues from selected overexpressed genes. Future
Oncol. 5:1641–1657. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Karst AM and Drapkin R: Ovarian cancer
pathogenesis: A model in evolution. J Oncol.
2010(932371)2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cobec IM, Sas I, Pirtea L, Cimpean AM,
Moatar AE, Ceaușu RA and Raica M: Podoplanin as key player of tumor
progression and lymph vessel proliferation in ovarian cancer.
Anticancer Res. 36:5265–5272. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Prat J: New insight into ovarian cancer
pathology. Ann Oncol. 23 (Suppl 10):S111–S117. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Murphy MA and Wentzensen N: Frequency of
mismatch repair deficiency in ovarian cancer: A systematic review.
Int J Cancer. 129:1914–1922. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li J, Fadare O, Xiang L, Kong B and Zheng
W: Ovarian serous carcinoma: Recent concepts on its origin and
carcinogenesis. J Hematol Oncol. 5(8)2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Markert EK, Levine AJ and Vazquez A:
Proliferation and tissue remodeling in cancer: The hallmarks
revisited. Cell Death Dis. 3(e397)2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kurman RJ and Shih IM: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kurman RJ and Shih IM: Molecular
pathogenesis and extraovarian origin of epithelial ovarian
cancer-shifting the paradigm. Hum Pathol. 42:918–931.
2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vang R, Shih IM and Kurman RJ: Ovarian
low-grade and high-grade serous carcinoma: Pathogenesis,
clinicopathologic and molecular biologic features, diagnostic
problems. Adv Anat Pathol. 16:267–282. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tew WP, Colombo N, Ray-Coquard I, Oza A,
del Campo J, Scambia G and Spriggs D: VEGF-trap for patients (pts)
with recurrent platinum-resistant epithelial ovarian cancer (EOC):
Preliminary results of a randomized, multicenter phase II study. J
Clin Oncol. 25 (Suppl 18)(S5508)2007.
|
|
23
|
Colombo N, Mangili G, Mammoliti S, Kalling
M, Tholander B, Sternas L, Buzenet G and Chamberlain D:
Aflibercept(VEGF Trap) for advanced epithelial ovarian cancer (EOC)
patients (pts) with symptomatic malignant ascites: Preliminary
results of a pilot study. J Clin Oncol. 26 (Suppl
15)(S14598)2008.
|
|
24
|
Leamon CP, Lovejoy CD and Nguyen B:
Patient selection and targeted treatment in the management of
platinum-resistant ovarian cancer. Pharmgenomics Pers Med.
6:113–125. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cimpean AM, Cobec IM, Ceaușu RA, Popescu
R, Tudor A and Raica M: Platelet derived growth factor BB: A
‘Must-have’ therapeutic target ‘Redivivus’ in ovarian cancer.
Cancer Genomics Proteomics. 13:511–517. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vrdoljak E, Wojtukiewicz MZ, Pienkowski T,
Bodoky G, Berzinec P, Finek J, Todorović V, Borojević N and
Croitoru A: South Eastern European Research Oncology Group. Cancer
epidemiology in Central, South and Eastern European countries.
Croat Med J. 52:478–487. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zheng L, Cui C, Shi O, Lu X, Li YK, Wang
W, Li Y and Wang Q: Incidence and mortality of ovarian cancer at
the global, regional, and national levels, 1990-2017. Gynecol
Oncol. 159:239–247. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shazly SA, Laughlin-Tommaso SK, Dowdy SC
and Famuyide AO: Staging for low malignant potential ovarian
tumors: A global perspective. Am J Obstet Gynecol. 215:153–168.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Matz M, Coleman MP, Carreira H, Salmerón
D, Chirlaque MD and Allemani C: CONCORD Working Group. Worldwide
comparison of ovarian cancer survival: Histological group and stage
at diagnosis (CONCORD-2). Gynecol Oncol. 144:396–404.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Warren JL, Harlan LC, Trimble EL, Stevens
J, Grimes M and Cronin KA: Trends in the receipt of guideline care
and survival for women with ovarian cancer: A population-based
study. Gynecol Oncol. 145:486–492. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shen F, Chen S, Gao Y, Dai X and Chen Q:
The prevalence of malignant and borderline ovarian cancer in pre-
and post-menopausal Chinese women. Oncotarget. 8:80589–80594.
2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Quaresma M, Coleman MP and Rachet B:
40-year trends in an index of survival for all cancers combined and
survival adjusted for age and sex for each cancer in England and
Wales, 1971-2011: A population-based study. Lancet. 385:1206–1218.
2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al: Global surveillance of cancer survival 1995-2009: Analysis
of individual data for 25,676,887 patients from 279
population-based registries in 67 countries (CONCORD-2). Lancet.
385:977–1010. 2015.PubMed/NCBI View Article : Google Scholar
|
